Dengue vaccines: the road to failure or to success?

References

• Halstead S, Thomas S. Dengue vaccines Plotkin’s Vaccines. 7th ed. Philadelphia (PA): Elsevier; 2018. p. 241–51.
   Google Scholar
• Blight J, Alves E, Reyes-Sandoval A. Considering genomic and immunological correlates of protection for a dengue intervention. Vaccines (Basel). 2019;7(4). doi:10.3390/vaccines7040203.
   PubMed Web of Science ®Google Scholar
• Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, … Wallace D. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;381(21):2009–19. doi:10.1056/NEJMoa1903869.
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, … Kirkpatrick BD. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis. 2017;11(5):e0005584. doi:10.1371/journal.pntd.0005584.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, … DiazGranados CA. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–40. doi:10.1056/NEJMoa1800820.
   PubMed Web of Science ®Google Scholar
• Arredondo-Garcia JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, … Zambrano B. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. 2018;24(7):755–63. doi:10.1016/j.cmi.2018.01.018.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, … Harris E. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32. doi:10.1126/science.aan6836.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Yoon IK. A review of Dengvaxia(R): development to deployment. Hum Vaccin Immunother. 2019;15(10):2295–314. doi:10.1080/21645515.2019.1658503.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine. 2017;35(47):6355–58. doi:10.1016/j.vaccine.2017.09.089.
   PubMed Web of Science ®Google Scholar
• Rosenbaum L. Trolleyology and the dengue vaccine dilemma. N Engl J Med. 2018;379(4):305–07. doi:10.1056/NEJMp1804094.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O’Brien K, Vannice K, … Nolan TM. Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2019;19(1):e31–e38. doi:10.1016/s1473-3099(18)30494-8.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Harris E. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine. 2017;35(36):4659–69. doi:10.1016/j.vaccine.2017.07.045.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019;393(10169):350–63. doi:10.1016/s0140-6736(18)32560-1.
   PubMed Web of Science ®Google Scholar
• Raut R, Corbett KS, Tennekoon RN, Premawansa S, Wijewickrama A, Premawansa G, … de Silva AM. Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies. Proc Natl Acad Sci U S A. 2019;116(1):227–32. doi:10.1073/pnas.1812055115.
   PubMed Web of Science ®Google Scholar
• Offit PA. Challenges to developing a rotavirus vaccine. Viral Immunol. 2018;31(2):104–08. doi:10.1089/vim.2017.0121.
   PubMed Web of Science ®Google Scholar
• Meer HC. Complexity in assessing the benefit vs risk of vaccines: experience with rotavirus and dengue virus vaccines. JAMA. 2019;322:1861. doi:10.1001/jama.2019.16206.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin Infect Dis. 2011;52(Suppl 3):s271–275. doi:10.1093/cid/ciq119.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Hombach J, Cravioto A. Misguided approach to dengue vaccine risk. Science. 2019;366(6469):1082–83. doi:10.1126/science.aaz6159.
   PubMed Web of Science ®Google Scholar
• Schmidt AC, Lin L, Martinez LJ, Ruck RC, Eckels KH, Collard A, … Thomas SJ. Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States. Am J Trop Med Hyg. 2017;96(6):1325–37. doi:10.4269/ajtmh.16-0634.
   PubMed Web of Science ®Google Scholar
• Borges MB, Marchevsky RS, Carvalho Pereira R, da Silva Mendes Y, Almeida Mendes LG, Diniz-Mendes L, … Warter L. Detection of post-vaccination enhanced dengue virus infection in macaques: an improved model for early assessment of dengue vaccines. PLoS Pathog. 2019;15(4):e1007721. doi:10.1371/journal.ppat.1007721.
   PubMed Web of Science ®Google Scholar
• Coronel D, Garcia-Rivera EJ, Rivera M, Arredondo-Garcia JL, Dietze R, Perroud AP, … Noriega F. Dengue vaccine booster in healthy adolescents and adults in Latin America: evaluation 4–5 years after a primary 3-dose schedule. Pediatr Infect Dis J. 2019;38(5):e90–e95. doi:10.1097/inf.0000000000002286.
   PubMed Web of Science ®Google Scholar
• Park J, Archuleta S, Oh MH, Shek LP, Jin J, Bonaparte M, … Bouckenooghe A. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series. Hum Vaccin Immunother. 2019:1–7. doi:10.1080/21645515.2019.1661204.
   PubMedGoogle Scholar
• Flasche S, Wilder-Smith A, Hombach J, Smith PG. Estimating the proportion of vaccine-induced hospitalized dengue cases among dengvaxia vaccinees in the philippines. Wellcome Open Res. 2019;4:165. doi:10.12688/wellcomeopenres.15507.1.
   PubMedGoogle Scholar
• Angelo MA, Grifoni A, O’Rourke PH, Sidney J, Paul S, Peters B, … Weiskopf D. Human CD4(+) T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J Virol. 2017;91:5. doi:10.1128/jvi.02147-16.
   Web of Science ®Google Scholar